Abdulraheem Yacoub, MD
About two-thirds of patients with hydroxyurea (Hydrea)-resistant/intolerant polycythemia vera (PV) or high-risk essential thrombocytopenia (ET) had objective responses to pegylated interferon alfa-2a, according to findings from a phase II study of salvage therapy presented at the 2017 ASH Annual Meeting.
One patient developed acquired clonal cytogenetic abnormalities during the trial. Three patients with PV had disappearance of baseline clonal abnormalities, and all 3 achieved CRs.
Yacoub A, Mascarnhas J, Kosiorek HE, et al. Single-arm salvage therapy with pegylated interferon alfa-2a for patients with high-risk polycythemia vera or high-risk essential thrombocythemia who are either hydroxyurea-resistant or intolerant: final results of the myeloproliferative disorders-research consortium (MPD-RC) protocol 111 global phase II trial. Presented at: 2017 ASH Annual Meeting; December 9-12, 2017; Atlanta, GA. Abstract 321.
... to read the full story